Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
|
|
- Ariel King
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: SAM40049 (150905) Title: A Danish, multi-centre, comparative, parallel-group study to determine whether initiation of combination treatment with Seretide (salmeterol + fluticasone propionate) 50/100 µg bd offers better asthma control than monotherapy with Flixotide (fluticasone propionate) 100 µg bd to adult asthmatic subjects uncontrolled on shortacting bronchodilator alone. Rationale: This clinical trial was designed to determine whether initiation of combination treatment with salmeterol (SAL) + fluticasone propionate (FP) improves asthma control greater than initiation of treatment with the inhaled corticosteroid, in asthmatic subjects uncontrolled on short-acting bronchodilator alone. Phase: IV Study Period: 8 May 2001 to 4 September Study Design: A multi-centre, randomised, controlled, double-blind, parallel-group, comparative study. Centres: 45 active centres in Denmark. Indication: Asthma. Treatment: Following a 2 week baseline period, subjects were randomised (1:1) to 1 of 2 treatment groups. Subjects either received 50/100 µg twice daily (bd) for 24 weeks or FP 100 µg bd for 24 weeks. Subjects were instructed to take 1 inhalation each morning and each evening. Objectives: The primary objective was to determine whether initiation of combination treatment with (50/100 µg bd) offers better asthma control, determined as fewer day+night s with symptoms, than initiation of monotherapy with FP (100 µg bd) to asthmatic subjects uncontrolled on short-acting bronchodilator alone. Primary Outcome/Efficacy Variable: The primary efficacy variable was symptom-free day+night s. Secondary Outcome/Efficacy Variable(s): The secondary efficacy variables were: morning peak expiratory flow (PEFam); evening peak expiratory flow (PEFpm); diurnal PEF variation; albuterol use, as needed (prn [pro re nata]); days and nights without albuterol prn use; day symptom score; night symptom score; symptom-free days; symptom-free nights; asthma exacerbations; episode-free day+night s (day symptom score = 0, night symptom score = 0, no albuterol prn use, no adverse events [AEs], no exacerbations); weeks with treatment success (+1 more symptom-free day+night /week vs. baseline mean); time to improved asthma control; subject treatment preference, and AEs. Statistical Methods: The percentage of symptom-free day+night s (psfree) was analysed using the analysis of variance (ANOVA) F-tests, allowing for effects due to treatment, subject, period and sequence. P-values and 95% confidence intervals (CI) for treatment differences were calculated. If normal distribution assumptions were not met, psfree was analysed using non-parametric alternatives testing for treatment difference. The Total Population comprised all subjects who entered the study; this population was used for tabulating reasons for withdrawal before randomisation. All subjects who entered the study and were randomised, with the exception of those for whom documented evidence existed that they did not take any treatment, were included in the Intent-to-Treat (ITT) Population; this population was used for all tables and analyses and was the primary population for the analysis of the primary endpoint, secondary endpoints and safety. Study Population: Male and non-pregnant female subjects using adequate contraception were eligible if they: were at least 18 years old; had been diagnosed with asthma, as defined by the American Thoracic Society with a clinical history of symptoms of episodic cough, wheezing, and dyspnea; had an asthma medical history of at least 3 months; and had only been treating their asthma with a short-acting bronchodilator, which had been used for relief of symptoms for at least 1 episode per week according to prescription, for at least 2 months prior to Visit 1. Subjects were eligible for randomisation, following the baseline period, if the following applied: a diary completed for at least 11 days and 11 nights; either diurnal PEF variation 20% on at least 2 days or one of the following must have been determined within 3 years prior to baseline: forced expiratory volume in 1 second (FEV1) reversibility 15% in response to bronchodilator, provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) 4 mg/ml, diurnal PEF variation 20%; mean relief medication (albuterol) use 1 episode/week; and day or night symptom score 1 at least once/week. Subjects were excluded if they had: upper or lower respiratory tract infection or middle ear infection within 1 month prior to Visit 1; problems with wrong or inadequate inhaler or peak flow meter technique; other lung diseases than asthma; known or suspected other diseases or situations likely to affect the outcome of the study results; and known serious cardiovascular disease, diabetes mellitus, untreated hypokalaemia, or thyrotoxicosis. Other exclusion criteria included: use of long-acting bronchodilators, inhaled corticosteroids, or other long-acting asthma medication within 2 1
2 months prior to Visit 1; use of daily oral corticosteroid treatment within 2 months of Visit 1 or oral corticosteroid therapy within 1 month prior to Visit 1; use of other medication that could affect the course of asthma or interfere with study results; known or suspected hypersensitivity reaction to drug recipients. Subjects with involvement in another clinical study with a study drug within 4 weeks prior to Visit 1 or during this study, or who had previously been randomised to this study were not eligible. Number of Subjects: Planned, N Randomised, N Completed, n (%) 67 (86) 59 (82) Total Number Subjects Withdrawn, n (%) 11 (14) 13 (18) Withdrawn due to Adverse Events, n (%) 1 (1) 2 (3) Withdrawn due to Lack of Efficacy, n (%) Not reported Not reported Withdrawn for Other Reasons, n (%) 10 (13) 11 (15) Demographics N (ITT) Females: Males 40: 38 45: 27 Mean Age, years (SD) 39.3 (15.4) 38.4 (15.1) Race, n (%) Not reported Not reported Primary Efficacy Results: (ITT Population) Percentage of symptom-free day+night s: Baseline period, N evaluable Mean percentage of psfree at baseline (SD) 19.5 (28.5) 23.7 (29.1) Run-in period, N evaluable Mean percentage of psfree at run-in (SD) 53.7 (36.6) 42.5 (37.9) Mean percentage of psfree at assessment (SD) 63.8 (34.6) 50.6 (36.9) 95% CI 55.2, , 59.3 Difference between treatments, vs FP % CI 0.94, p-value Secondary Outcome Variable(s): (ITT Population) PEFam: Mean PEFam at baseline (SD) (117.0) (108.7) Mean PEFam at run-in (SD) (126.9) (116.7) Mean PEFam at assessment (SD) (130.2) (126.0) 95% CI 405.8, , Difference between treatments, vs FP % CI , PEFpm: Mean PEFpm at baseline (SD) (123.5) (113.3) Mean PEFpm at run-in (SD) (127.9) (118.0) Mean PEFpm at assessment (SD) (127.5) (125.8) 95% CI 418.4, , Difference between treatments, vs FP
3 95% CI , Diurnal PEF variation: Mean diurnal PEF at baseline (SD) 6.1 (10.1) 4.6 (5.7) Mean diurnal PEF at run-in (SD) 2.7 (6.3) 3.2 (5.4) Mean diurnal PEF at assessment (SD) 2.6 (6.4) 2.6 (4.8) 95% CI 1.2, , 4.0 Difference between treatments, vs FP % CI -1.95, 1.89 Albuterol prn use: Mean albuterol use at baseline (SD), episodes per day+night 2.3 (1.7) 2.1 (1.3) Run-in period, N evaluable Mean albuterol use at run-in (SD) 1.1 (1.2) 1.7 (1.7) Assessment period, N evaluable Mean albuterol use at assessment (SD) 1.1 (1.2) 1.3 (1.2) 95% CI 0.8, , 1.6 Difference between treatments, vs FP % CI -0.61, 0.24 Day+night s without albuterol prn use: Mean percentage of days/nights without use at baseline (SD) 21.5 (29.4) 24.8 (29.3) Run-in period, N evaluable Mean percentage of days/nights without use at run-in (SD) 63.2 (35.9) 47.5 (37.7) Mean percentage of days/nights without use at assessment (SD) 70.8 (33.4) 62.5 (34.6) 95% CI 62.6, , 70.8 Difference between treatments, vs FP % CI -3.38, Day symptom score: Baseline period, N evaluable Mean day symptom score at baseline (SD) 1.4 (0.8) 1.3 (0.9) Run-in period, N evaluable Mean day symptom score at run-in (SD) 0.7 (0.7) 0.9 (1.0) Mean day symptom score at assessment (SD) 0.5 (0.6) 0.7 (0.9) 95% CI 0.3, , 0.9 Difference between treatments, vs FP % CI -0.48, 0.03 Night symptom score: Mean night symptom score at baseline (SD) 0.6 (0.6) 0.5 (0.5) Run-in period, N evaluable Mean night symptom score at run-in (SD) 0.3 (0.4) 0.4 (0.5) Assessment period, N evaluable Mean night symptom score at assessment (SD) 0.2 (0.4) 0.2 (0.3) 95% CI 0.1, , 0.3 Difference between treatments, vs FP % CI , Percentage of symptom-free days: Baseline period, N evaluable Mean percentage of symptom-free days at baseline (SD) 24.6 (31.6) 30.7 (31.9) Run-in period, N evaluable
4 Mean percentage of symptom-free days at run-in (SD) 55.8 (37.5) 49.6 (37.8) Mean percentage of symptom-free days at assessment (SD) 65.8 (33.8) 56.6 (36.1) 95% CI 57.4, , 65.1 Difference between treatments, vs FP % CI -2.74, Percentage of symptom-free nights: Mean percentage of symptom-free nights at baseline (SD) 55.8 (36.7) 61.1 (34.8) Run-in period, N evaluable Mean percentage of symptom-free nights at run-in (SD) 78.6 (29.2) 73.5 (31.1) Assessment period, N evaluable Mean percentage of symptom-free nights at assessment (SD) 82.8 (27.7) 80.4 (26.7) 95% CI 76.3, , 87.0 Difference between treatments, vs FP % CI -6.86, Asthma exacerbations: N evaluable Subjects with asthma exacerbation, n (%) 1 (1) 1 (1) Subjects without asthma exacerbation, n (%) 74 (99) 69 (99) Episode-free day+night s: Baseline period, N evaluable Mean percentage of episode-free days at baseline (SD) 14.8 (26.0) 17.0 (25.4) Run-in period, N evaluable Mean percentage of episode-free days at run-in (SD) 49.0 (36.8) 36.8 (36.4) Mean percentage of episode-free days at assessment (SD) 60.0 (36.1) 46.7 (37.2) 95% CI 51.2, , 55.6 Difference between treatments, vs FP % CI 0.79, Weeks with treatment success: Assessment period, N evaluable Mean percentage of psfree at assessment (SD) 14.1 (8.9) 12.1 (9.2) Time to improved asthma control (days): A definition of improved asthma control was not defined pre-study or pre-analysis. Therefore not determined. If defined and analysed later the analysis will clearly be marked post-hoc. N evaluable Mean time to improved asthma control (SD) Subject treatment preference: N evaluable Prefer the same drug in the future n (%) Yes 46 (79) 30 (60) No 8 (14) 12 (24) Don t know 3 (5) 8 (16) Safety Results: ITT Population - All AEs and serious adverse events (SAEs) occurring during the treatment period of the study, from Visit 1 to Follow-up, were reported. Most Frequent Adverse Events On-Therapy n (%) n (%) Subjects with any AE(s), n (%) 48 (62) 42 (58) Headache 17 (22) 23 (32) Common cold 6 (8) 6 (8) Cough 4 (5) 6 (8) Back pain 4 (5) 3 (4) 4
5 Myalgia(s) 3 (4) 1 (1) Odontalgia 2 (3) 2 (3) Hay fever 2 (3) 1 (1) Influenza 2 (3) 1 (1) Oral candidiasis 2 (3) 1 (1) Sore throat 2 (3) 1 (1) Allergic conjunctivitis 2 (3) 0 Arthralgia 2 (3) 0 Bronchitis 2 (3) 0 Hoarseness 2 (3) 0 Nasal congestion 2 (3) 0 Tachycardia 2 (3) 0 Tonsillitis 2 (3) 0 Eczema 1 (1) 3 (4) Psychiatric depression 1 (1) 3 (4) Sinusitis 1 (1) 3 (4) Gastric pain 1 (1) 2 (3) Shoulder pain 1 (1) 2 (3) Cystitis 0 2 (3) Diarrhea 0 2 (3) Dysmenorrhea 0 2 (3) Fever 0 2 (3) Gastric disorder 0 2 (3) Neck pain 0 2 (3) Pneumonia 0 2 (3) Pruritus 0 2 (3) Recurrent sore throat 0 2 (3) Serious Adverse Events - On-Therapy n (%) [n considered by the investigator to be related to study medication] Subjects with non-fatal SAEs, n (%) 1 (1) 2 (3) Suspected asthma exacerbation 1 (1) [0] 0 Fracture of the tibia 0 1 (1) [0] Ascites 0 1 (1) [0] Subjects with fatal SAEs, n (%) 0 1 (1) Death 0 1 (1) [0] Conclusion: See publications below Publications: Strand AM & Luckow A: Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate. Respiratory Medicine 2004, 98: Strand AM & Luckow A: Initiation of treatment with salmeterol/fluticasone propionate combination product is more effective than inhaled steroid alone in asthmatic patients symptomatic on short-acting bronchodilator alone, ERS 2003 Date Updated: 07-Dec
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)
Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSecondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS
Study No.: A3007 Title: A Randomized, Double-Blind, -Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationSYNOPSIS. Date 15 June 2004
Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
he study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAnalysis of immunogenicity
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).
Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Study centres This was a multicentre study conducted in 53 centres in Sweden.
Drug product: Symbicort Turbuhaler Drug substance(s): Budesonide/Formoterol Edition No.: 1 Study code: LD-039-0003 Date: 20 May 2005 SYNOPSIS An open, randomized, parallel group, multicentre, phase IIIB
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe Asthma Guidelines: Diagnosis and Assessment of Asthma
The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBlood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement
Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor Novartis Consumer Health, SA. Generic Drug Name
Sponsor Novartis Consumer Health, SA Generic Drug Name Xylometazoline Hydrochloride Trial Indication(s) For the symptomatic relief of nasal congestion due to colds, hayfever or other allergic rhinitis,
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004
Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationStudy No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1833/5/06 ASTRAZENECA v GLAXOSMITHKLINE CONCEPT study leavepiece AstraZeneca complained that a leavepiece issued by Allen & Hanburys, part of GlaxoSmithKline, did not present a fair and balanced
More informationCHALLENGES OF REAL LIFE ASTHMA MANAGEMENT. Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board
CHALLENGES OF REAL LIFE ASTHMA MANAGEMENT Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board CONFLICT OF INTEREST Employee of Auckland District Health
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPublic Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended.
Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Bricanyl () DK/W/0017/pdWS/001 Rapporteur: Denmark Finalisation procedure
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone
More informationGSK Medicine: Study Number:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationTREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationmeasured Improvement in am PEFR FP vs BUD gave +11l/min FP vs BDP gave nonsignificant improvement in PEFR +3l/min FP: BUD ratio 1.
1 of 8 09/05/2018, 11:29 Guideline topic: Pharmacological management of asthma Evidence table 4.25: Budesonide vs Beclomethasone Different inhaled corticosteroids (ICS) flixotide propionate (FP) vs budesonide
More informationWho can get most benefit
Who can get most benefit from tiotropium in asthma? Y-M. Oh Asan Medical Center Univ. of Ulsan College of Medicine Seoul, Korea Tiotripium for Asthma 1 New in GINA 2015 Add-on tiotropium by soft-mist inhaler
More information3 RESPIRATORY SYSTEM
3 RESPIRATORY SYSTEM 3.01 ANTIASTHMATICS 3.01a BETA 2 AGONIST ASTHMA, CHRONIC BRONCHITIS & EMPHYSEMA Salbutamol Inhaler 100ug/dose [Albuterol] (Ventolin) Salbutamol Sulphate Respirator Solution 0.5% (5mg/ml),
More information